The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer von Myerson, J.S, Faria, A, Puglisi, M, Starling, N, Popat, S, O’Brien, M.E.R

Volltext

A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12weeks von O’Brien, M.E.R., Myerson, J.S., Coward, J.I.G., Puglisi, M., Trani, L., Wotherspoon, A., Sharma, B., Cook, G., Ashley, S., Gunapala, R., Chua, S., Popat, S.

Volltext

Chronic obstructive pulmonary disease in lung cancer – underdiagnosed and undertreated von Myerson, J.S, Priest, K, Power, F, Ashley, S, O'Brien, M.E.R

Volltext

An audit of neutropaenia in patients with small cell lung carcinoma (SCLC) undergoing platinum-based chemotherapy – urgent need for specific SCLC guidelines von Benning, J, Starling, N, Myerson, J.S, Popat, S, Ashley, S, O'Brien, M.E.R

Volltext

Audit of epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) using Dako and Ventana clones in non-small cell lung cancer (NSCLC) von Baird, R, Mikropoulos, C, Ashley, S, Killick, E, Myerson, J.S, Wotherspoon, A, O'Brien, M.E.R, Popat, S, Jackson-Jones, R

Volltext

The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer (NSCLC) patients von Faria, A, Myerson, J.S, Puglisi, M, Starling, N, Ashley, S, Popat, S, O'Brien, M.E.R, Bruzynski, P

Volltext

9062 The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer (NSCLC) patients von Faria, A, Myerson, J.S, Puglisi, M, Starling, N, Ashley, S, Popat, S, O'Brien, M.E.R

Volltext

A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12 weeks von O’Brien, M.E.R., Myerson, J.S., Coward, J.I.G., Puglisi, M., Trani, L., Wotherspoon, A., Sharma, B., Cook, G., Ashley, S., Gunapala, R., Chua, S., Popat, S.

Volltext

A phase II study of18 F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12 weeks von O’Brien, M.E.R, Myerson, J.S, Coward, J.I.G, Puglisi, M, Trani, L, Wotherspoon, A, Sharma, B, Cook, G, Ashley, S, Gunapala, R, Chua, S, Popat, S

Volltext

RSA REPORT von S.C., Myerson, Jeremy, J.S.

Volltext